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ong  term  effect  of switching  to darunavir/ritonavir
n HIV  infected  patients  previously  on  protease
sus T12 200.1 ± 31.8 mg/dL, p < 0.001; LDL at T0 139.3 ± 43.4,nhibitor therapy
he incidence of dyslipidemia is signiﬁcantly higher in
atients treated with antiretroviral regimens contain-
ng ritonavir compared to other regimens not containing
itonavir.1 Moreover, protease inhibitors (PIs) are not
qually prone to impair the lipid proﬁle. Regimens with
opinavir/ritonavir (LPV/r) and fosamprenavir/ritonavir (FPV/r)
ndeed, induce greater elevations in lipid parameters than
aquinavir/ritonavir (SQV/r) or atazanavir/ritonavir (ATV/r) or
arunavir/ritonavir (DRV/r).2 The objective of this study was
o explore the impact on the lipid proﬁle of switching from
older PIs” to DRV/r in virologically suppressed HIV infected
atients after 144 weeks of observation. A prospective open
abel single center study enrolled a total of 13 Caucasian
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ig. 1 – Lipid proﬁle of patients: total cholesterol (TCh), LDL chole
nd at different controls of follow-up. *p < 0.05, **p < 0.01, ***p < 0.0subjects who switched to DRV/r at dosage 800 mg/100 mg,
without keeping the same NRTI backbone.
The switch to DRV/r reduced triglycerides levels, total and
LDL cholesterol right after three months. Similar improve-
ments remained stable during the follow up period. At the
end of the study a signiﬁcant reduction of triglycerides (TGs),
total (TCh) and LDL cholesterol were in the order of 47%,
18%, and 18%, respectively (TGs at T0 383.7 ± 70.2 versus
T12 202.4 ± 60.7 mg/dL, p < 0.001, TCh at T0 244.7 ± 51.3 ver- 1.00
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sterol (LDL), cystatin C and triglycerides (TGs) at baseline
01 contrast analysis versus the previous follow-up control.
versus T12 114.1 ± 30.7 mg/dL, p < 0.01) (Fig. 1). In addition,
the TCh/HDL ratio has also improved (p = 0.004). Increases
in CD4+ cell counts and in CD4/CD8 ratio (p < 0.05) were
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also observed. Serum cystatin C values showed a statisti-
cally signiﬁcant decrease during the follow up period (T0
0.84 ± 0.16 versus 0.78 ± 0.20 mg/dL, p = 0.046). After 144 weeks
the switch from LPV/r or FPV/r to DRV/r in HIV infected
patients with triglycerides higher than 200 mg/dL, induced a
sustained improvement on the lipid parameters, and speciﬁ-
cally a reduction of main lipid makers. These effects may be
explained by the reduced booster dose of ritonavir (200 mg  to
100 mg), and by a smaller impact of DRV on lipid parameters
as compared to other PIs containing regimens, as previ-
ously showed. In this study, it should be pointed out that
this improvement was long-lasting with excellent HIV-RNA
control; all patients completed the study without virological
failure. Of note, we  observed an improvement in TCh/HDL
ratio another strong surrogate marker for predicting cardio-
vascular events as previously demonstrated in HIV negative
population.3 In this study we  showed an improvement in
different surrogate markers of CD risk, such as TGs, TCh,
LDL, TCh/HDL ratio, conﬁrming data previously published4
and the long-term efﬁcacy of this strategy. An interesting
result of this study is the signiﬁcant reduction of cystatin
C serum levels at every time point of observation reaching
8% at 144 weeks. Moreover, a signiﬁcant decrease of microal-
buminuria was observed with a reduction of 35% at the
end of the study, in patients without renal impairment or
decreased glomerular ﬁltration rate. This is the ﬁrst signiﬁcant
data on microalbuminuria after switching PIs. Cardiovascular
risk reduction is also supported by improvement in cystatin
C and microalbuminuria which are important markers of
inﬂammatory status, CD risk, and mortality.5 The contin-
uous increase in CD4+ cell counts after switching PIs and
a remarkable signiﬁcant improvement in CD4/CD8 ratio are
surrogate markers of important immune reconstitution. In
conclusion, in HIV infected patients on antiretroviral therapy
and with abnormal lipid proﬁles, switching to DRV/r must
be considered for long term containment of the metabolic
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